BRIP1 anticorps (C-Term)

N° du produit ABIN965699

L’anticorps Lapin Polyclonal anti-BRIP1 a été validé pour IHC. Il convient pour détecter BRIP1 dans des échantillons de Humain. Il y a 2+ publications disponibles.

Aperçu rapide pour BRIP1 anticorps (C-Term) (ABIN965699)

Antigène: BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp BRIP1 est non-conjugé

Application: Immunohistochemistry (IHC)

Détail du produit anti-BRIP1 anticorps

Épitope: C-Term

Immunogène: Polyclonal antibody produced in rabbits immunizing with a synthetic peptide corresponding to C-terminal residues of human BRIP1(ATP-dependent RNA helicase)

Information d'application

Restrictions: For Research Use only

Stockage

Stock: 4 °C

Références pour anticorps anti-BRIP1 (ABIN965699)

Cantor, Drapkin, Zhang, Lin, Han, Pamidi, Livingston: "The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations." dans: Proceedings of the National Academy of Sciences of the United States of America, Vol. 101, Issue 8, pp. 2357-62, (2004) (PubMed).

Yu, Chini, He, Mer, Chen: "The BRCT domain is a phospho-protein binding domain." dans: Science (New York, N.Y.), Vol. 302, Issue 5645, pp. 639-42, (2003) (PubMed).

Détails sur BRIP1

Antigène: BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1 (BRIP1))

Autre désignation: BRIP1

Sujet: BRIP1(ATP-dependent RNA helicase Is a DNA-dependent ATPase and 5' to 3' DNA helicase which is required for the maintenance of chromosomal stability. BRIP1 acts late in the Fanconi anemia pathway, after FANCD2 ubiquitination. BRIP1 is involved in the repair of DNA double-strand breaks by homologous recombination in a manner that depends on its association with BRCA1. BRIP1 binds directly to the BRCT domains of BRCA1. BRIP1 is ubiquitously expressed, with highest levels in testis. Defects in BRIP1 are a cause of susceptibility to breast cancer (BC). BC is an extremely common malignancy, affecting one in eight women during their lifetime. A positive family history has been identified as major contributor to risk of development of the disease, and this link is striking for early-onset breast cancer. At the cellular level it is associated with hypersensitivity to DNA-damaging agents, chromosomal instability (increased chromosome breakage), and defective DNA repair.
Synonyms: FACJ (Fanconi anemia group J protein), BRCA1(interacting protein C-terminal helicase 1)

Pathways: Réparation de l'ADN